Pharmacologic evidence for abnormal thalamocortical functioning in GABAA receptor β3 subunit-deficient mice, a model of Angelman syndrome

Epilepsia

Volumn 46, Issue 12, 2005, Pages 1860-1870

  Handforth, Adrian ^a,e   DeLorey, Timothy M ^b,d   Homanics, Gregg E ^c   Olsen, Richard W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MOLECULAR RESEARCH INSTITUTE   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Angelman; Electroencephalogram; Ethosuximide; GABA receptor; Seizures; Thalamus

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; FOSPHENYTOIN SODIUM; RECEPTOR SUBUNIT; VALPROIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ORGANOPHOSPHORUS COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; ELECTRODE; ELECTROENCEPHALOGRAM; HAPPY PUPPET SYNDROME; IMPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; THALAMUS; ANIMAL; BRAIN CORTEX; DISEASE MODEL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MALE; METABOLISM; MOUSE MUTANT; NERVE TRACT; PARIETAL LOBE; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICS;

ANGELMAN SYNDROME; ANIMALS; ANTICONVULSANTS; BACLOFEN; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; ETHOSUXIMIDE; FEMALE; GABA AGONISTS; GABA ANTAGONISTS; HUMANS; MALE; MICE; MICE, MUTANT STRAINS; NEURAL PATHWAYS; ORGANOPHOSPHORUS COMPOUNDS; PARIETAL LOBE; RECEPTORS, GABA-A; THALAMUS;

EID: 33644813408     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00287.x     Document Type: Article

References (49)

1. Williams CA, Angelman H, Clayton-Smith J, et al. Angelman syndrome: consensus for diagnostic criteria: Angelman Syndrome Foundation. Am J Med Genet 1995;56:237-8.
2. Guerrini R, DeLorey TM, Bonanni P, et al. Cortical myoclonus in Angelman syndrome. Ann Neurol 1996;40:39-48.
3. Jiang Y, Lev-Lehman E, Bressler J, et al. Genetics of Angelman syndrome. Am J Hum Genet 1999;65:1-6.
4. Jiang YH, Armstrong D, Albrecht U, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998;21:799-811.
5. A receptor. J Neurosci 2002;22:5572-80.
6. Culiat CT, Stubbs LJ, Montgomery CS, et al. Phenotypic consequences of deletion of the α3, α5, or α3 subunit of the type A α-aminobutyric acid receptor in mice. Proc Natl Acad Sci USA 1994;91:2815-8.
7. Homanics GE, DeLorey TM, Firestone LL, et al. Mice devoid of gamma-aminobutyrate type A receptor β3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Proc Natl Acad Sci USA 1997;94:4143-8.
8. A receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci 1998;18:8505-14.
9. A receptor alterations. Neurosci Lett 2003;340:205-8.
10. A receptor β3 subunit deletions. Ann Neurol 2001;49:110-3.
11. Odano I, Anezaki T, Ohkubo M, et al. Decrease in benzodiazepine receptor binding in a patient with Angelman syndrome detected by iodine-123 iomazenil and single-photon emission tomography. Eur J Nucl Med 1996;23:598-604.
12. Huntsman MM, Porcello DM, Homanics GE, et al. Reciprocal inhibitory connections and network synchrony in the mammalian thalamus. Science 1999;283:541-3.
13. McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 2001;63:815-46.
14. Terman D, Bose A, Kopell N. Functional reorganization in thalamocortical networks: transition between spindling and delta sleep rhythms. Proc Natl Acad Sci U S A 1996;93:15417-22.
15. Blumenfeld H, McCormick DA. Corticothalamic inputs control the pattern of activity generated in thalamocortical networks. J Neurosci 2000;20:5153-62.
16. Bal T, Debay D, Destexhe A. Cortical feedback controls the frequency and synchrony of oscillations in the visual thalamus. J Neurosci 2000;20:7478-88.
17. Dossi RC, Nunez A, Steriade M. Electrophysiology of a slow (0.5-4 Hz) intrinsic oscillation of cat thalamocortical neurones in vivo. J Physiol 1992;447:215-34.
18. Pape HC, Munsch T, Budde T. Novel vistas of calcium-mediated signalling in the thalamus. Pflugers Arch 2004;448:131-8.
19. Bal T, von Krosigk M, McCormick DA. Role of the ferret perigeniculate nucleus in the generation of synchronized oscillations in vitro. J Physiol 1995;483:665-85.
20. Bal T, von Krosigk M, McCormick DA. Synaptic and membrane mechanisms underlying synchronized oscillations in the ferret lateral geniculate nucleus in vitro. J Physiol 1995;483:641-63.
21. B-mediated inhibition in thalamic relay neurons through effects in nucleus reticularis. J Neurophysiol 1994;71:2576-81.
22. Sanchez-Vives MV, McCormick DA. Functional properties of perigeniculate inhibition of dorsal lateral geniculate nucleus thalamocortical neurons in vitro. J Neurosci 1997;17:8880-93.
23. Sohal VS, Huntsman MM, Huguenard JR. Reciprocal inhibitory connections regulate the spatiotemporal properties of intrathalamic oscillations. J Neurosci 2000;20:1735-45.
24. Snead OC 3rd. Pharmacological models of generalized absence seizures in rodents. J Neural Transm Suppl 1992;35:7-19.
25. B receptor activation in absence seizures of lethargic (lh/lh) mice. Science 1992;257:398-401.
26. Aizawa M, Ito Y, Fukuda H. Pharmacological profiles of generalized absence seizures in lethargic, stargazer and gammahydroxybutyrate-treated model mice. Neurosci Res 1997;29:17-25.
27. B receptor antagonist, in the lethargic mouse, gamma-hydroxybutyrate, and pentylenetetrazole models. J Pharmacol Exp Ther 1995;274:1399-403.
28. B antagonist CGP-35348 blocks spike-wave bursts in the cholesterol synthesis rat absence epilepsy model. Brain Res 1996;729:147-50.
29. Urbanska EM, Blaszczak P, Saran T, et al. Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice. Eur J Pharmacol 1998;359:55-8.
30. Ferraz AC, Pereira LF, Ribeiro RL, et al. Ricinine-elicited seizures. Anovel chemical model of convulsive seizures. Pharmacol Biochem Behav 2000;65:577-83.
31. Suzuki Y, Edge J, Mimaki T, et al. Intermittent clonazepam treatment prevents anticonvulsant tolerance in mice. Epilepsy Res 1993;15:15-20.
32. Voigt JP, Morgenstern E, Fink H. Memory-enhancing effects of benzodiazepines in mice. Eur Neuropsychopharmacol 1996;6:253-55.
33. Bichard AR, Little HJ. Drugs that increase gamma-aminobutyric acid transmission protect against the high pressure neurological syndrome. Br J Pharmacol 1982;76:447-52.
34. Czuczwar SJ, Janusz W, Wamil A, et al. Inhibition of aminophylline- induced convulsions in mice by antiepileptic drugs and other agents. Eur J Pharmacol 1987;144:309-15.
35. Czuczwar SJ, Turski L, Turski W, et al. Effects of some antiepileptic drugs in pentylenetetrazol-induced convulsions in mice lesioned with kainic acid. Epilepsia 1981;22:407-14.
36. Heller AH, Dichter MA, Sidman RL. Anticonvulsant sensitivity of absence seizures in the tottering mutant mouse. Epilepsia 1983;24:25-34.
37. Dellovade TL, Davis AM, Ferguson C, et al. GABA influences the development of the ventromedial nucleus of the hypothalamus. J Neurobiol 2001;49:264-76.
38. A receptor β3 subunit deletion decreases α2/3 subunits and IPSC duration. J Neurophysiol 2003;89:128-34.
39. A receptor β3 subunit gene-deficient heterozygous mice showparent-of-origin and gender-related differences in β3 subunit levels, EEG and behavior. Dev Brain Res 2005;157:150-61.
40. Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38:408-14.
41. Kuenzle C, Steinlin M, Wohlrab G, et al. Adverse effects of vigabatrin in Angelman syndrome. Epilepsia 1998;39:1213-15.
42. Ruggieri M, McShane MA. Parental view of epilepsy in Angelman syndrome: a questionnaire study. Arch Dis Child 1998;79:423-6.
43. B receptors decreases EEG synchronization. Neurosci Lett 1994;172:155-8.
44. Leresche N, Parri HR, Erdemli G, et al. On the action of the antiabsence drug ethosuximide in the rat and cat thalamus. J Neurosci 1998;18:4842-53.
45. Gomora JC, Daud AN, Weiergraber M, et al. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 2001;60:1121-32.
46. A receptor subtype-specific modulation of the synchrony and duration of thalamic oscillations. J Neurosci 2003;23:3649-57.
47. Gigli GL, Gotman J. Effects of seizures and carbamazepine on interictal spiking in amygdala kindled cats. Epilepsy Res 1991;8:204-12.
48. Nolt DH, Mott JM, Lopez WL. Assessment of anticonvulsant effectiveness and safety in patients with Angelman's syndrome using an Internet questionnaire. Am J Health Syst Pharm 2003;60:2583-7.
49. A receptor subunit. Neurology 2001;57:1518-9.